PRIMARY MALIGNANT-LYMPHOMA OF THE PAROTID-GLAND

Citation
L. Barnes et al., PRIMARY MALIGNANT-LYMPHOMA OF THE PAROTID-GLAND, Archives of otolaryngology, head & neck surgery, 124(5), 1998, pp. 573-577
Citations number
39
Categorie Soggetti
Otorhinolaryngology,Surgery
ISSN journal
08864470
Volume
124
Issue
5
Year of publication
1998
Pages
573 - 577
Database
ISI
SICI code
0886-4470(1998)124:5<573:PMOTP>2.0.ZU;2-J
Abstract
Objectives: To document the clinicopathologic features of primary mali gnant lymphoma of the parotid gland based on analysis of our cases and to compare the results with similar studies in the literature. Design : Retrospective, nonrandomized case study. Setting: Academic, tertiary medical center. Patients: Forty-one consecutive cases of malignant ly mphomas of the parotid gland were identified among 820 patients who ha d undergone parotid surgery during the course of 22 years. Thirty-thre e (80%) of these were primary lymphomas and were included in the study . Eight (20%) occurred in patients with a history of malignant lymphom a and were therefore excluded. Intervention: Diagnosis was established by open parotid biopsy in 8 patients, superficial lobectomy in 23, an d total parotidectomy in 2. After diagnosis, lymphomas were staged and treated with local irradiation and/or chemotherapy. Results: Fifteen men and 18 women aged 26 to 100 years (mean, 66 years) had an enlargin g painless mass on initial examination. Seven (21%) had an underlying autoimmune disease and 20 (61%) had Ann Arbor stage I disease at diagn osis. Of 25 patients available for a minimum 2-year follow-up, 16 (64% ) were alive with or without disease. Histological grade was the only prognostic feature associated with outcome (P<.01). Conclusions: Our s tudy, when viewed collectively with those in the literature, indicates that malignant lymphomas of the parotid gland are uncommon and often not suspected clinically. The disease affects both sexes equally and i s unusual before the age of 50 years. Most are B-cell, non-Hodgkin lym phomas, and about 80% of patients have Ann Arbor stage I or II disease at diagnosis.